News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Infinity Pharmaceuticals Inc. (INFI) Pulls Plug on Cancer Drug Saridegib Trials


6/18/2012 7:37:26 AM

Infinity Pharmaceuticals Inc. is stopping its Phase 2 trials of its experimental drug, saridegib, to treat bone and cartilage cancers, saying results have been disappointing. The drug developer said its analysis of the use of saridegib by patients with chrondrosarcoma, a rare and life-threatening cancer of the cartilage, found that results were similar to a placebo. Infinity also said it will discontinue its Phase 2 trial of saridegib in patients with myelofibrosis, an incurable malignancy of the bone marrow, based on data from the cohort of 12 patients that could be evaluated.

Read at Market Watch
Read at RTT News
Read at BusinessWeek
Read at Wall Street Journal


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES